Human Tissue Inhibitor of Metalloproteinases 3 Interacts with Both the N- and C-terminal Domains of Gelatinases A and B
REGULATION BY POLYANIONS*

Georgina S. ButlerDagger , Suneel S. Apte§, Frances Willenbrock, and Gillian MurphyDagger parallel **

From the Dagger  School of Biological Sciences, University of East Anglia, Norwich, Norfolk NR4 7TJ, United Kingdom, the § Department of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195, and the  Laboratory of Structural and Mechanistic Enzymology, Department of Biochemistry, Queen Mary and Westfield College, University of London, London E1 4NS, United Kingdom

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

We compared the association constants of tissue inhibitor of metalloproteinases (TIMP)-3 with various matrix metalloproteinases with those for TIMP-1 and TIMP-2 using a continuous assay. TIMP-3 behaved more like TIMP-2 than TIMP-1, showing rapid association with gelatinases A and B. Experiments with the N-terminal domain of gelatinase A, the isolated C-terminal domain, or an inactive progelatinase A mutant showed that the hemopexin domain of gelatinase A makes an important contribution to the interaction with TIMP-3. The exchange of portions of the gelatinase A hemopexin domain with that of stromelysin revealed that residues 568-631 of gelatinase A were required for rapid association with TIMP-3. The N-terminal domain of gelatinase B alone also showed slower association with TIMP-3, again implying significant C-domain interactions. The isolation of complexes between TIMP-3 and progelatinases A and B on gelatin-agarose demonstrated that TIMP-3 binds to both proenzymes. We analyzed the effect of various polyanions on the inhibitory activity of TIMP-3 in our soluble assay. The association rate was increased by dextran sulfate, heparin, and heparan sulfate, but not by dermatan sulfate or hyaluronic acid. Because TIMP-3 is sequestered in the extracellular matrix, the presence of certain heparan sulfate proteoglycans could enhance its inhibitory capacity.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The tissue inhibitors of metalloproteinases (TIMPs)1 are specific protein inhibitors of the matrix metalloproteinases (MMPs), a group of zinc-dependent enzymes that include collagenases, gelatinases, and stromelysins. Four forms of human TIMP have been cloned: TIMP-1 (1), TIMP-2 (2), TIMP-3 (3-6), and, more recently, TIMP-4 (7). TIMP-1 and TIMP-2 are secreted by many cell types in culture and are found in body fluids and tissue extracts. TIMP-3 is unique in that it appears to be a component of the extracellular matrix (8-10) and occurs in relatively small amounts, possibly being expressed during specific cellular events (11).

The TIMPs have comparable abilities to inhibit the active forms of the MMPs when assessed using macromolecular substrates (12, 13) and have been shown to make tight binding noncovalent complexes with active MMPs with a 1:1 stoichiometry (14-17). The inhibitors have related primary and secondary structures, consisting of an N-terminal subdomain of three disulfide bonded loops and a smaller C-terminal region also containing three loops (18-20). The N-terminal domain of TIMP-1 and TIMP-2 can act as a functional inhibitor (19, 21, 22), interacting with the catalytic domain of the enzymes such that competition with low molecular weight substrate analogue inhibitors can be observed (23).2 Using peptide substrate assays, it has been possible to demonstrate that TIMP-MMP complexes interact with Ki values of 10-9 to 10-12 M (24). Comparative studies of the association rates of TIMP-1 and TIMP-2 with different members of the MMP family in our laboratory have shown exceptionally strong C-terminal domain interactions between TIMP-1 and gelatinase B and between TIMP-2 and gelatinase A, suggesting that complexes between the respective pro forms of these enzymes, the active sites of which are inaccessible, and inhibitors can also occur (20, 25, 26). This supports other biochemical studies of these complexes (27-30).

In this study, we have assessed the ability of TIMP-3 to associate with active MMPs using a kinetic method, and we have compared this with TIMP-1 and TIMP-2. We have also investigated the contribution of the C-terminal domains of both gelatinase A and gelatinase B to the interaction with TIMP-3, because this has important implications for the regulation of proenzyme activation. We have tested the effect of heparin and other polyanions on TIMP-3 activity in our soluble kinetic assay to determine whether interaction with similar components of the extracellular matrix could affect the capacity of TIMP-3 to inhibit MMPs.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials-- All chemicals and reagents were purchased from Sigma, ICN Flow, or Pierce unless stated otherwise. Quenched fluorescent peptides (7-methoxycoumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)-Ala-Arg-NH2 (Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2) and (7-methoxycoumarin-4-yl)acetyl-Pro-Leu-Ala-Norval-(3-(2, 4-dinitrophenyl)-L-2,3-diaminopropionyl)-Ala-Arg-NH2 (Mca-Pro-Leu-Ala-Nva-Dpa-Ala-Arg-NH2) were made by Dr C. G. Knight (Biochemistry Department, University of Cambridge, Cambridge, United Kingdom). The following polyanions were purchased from Sigma: heparin (porcine intestinal mucosa, H3149); de-N-sulfated heparin (porcine intestinal mucosa, D4776); heparan sulfate (bovine kidney, H7640; bovine intestinal mucosa, H7641); hyaluronic acid (human umbilical cord, H1504); dermatan sulfate (chondroitin sulfate B; bovine mucosa, C0320); dextran sulfate (average Mr 10,000; D6924).

Preparation of TIMPs and Gelatinases-- TIMP-1, TIMP-2, and TIMP-3 were expressed from NS0 myeloma cells and purified as described previously (13, 19, 20). Progelatinase A, (Delta 1-414)gelatinase A, pro(Delta 418-631)gelatinase A, and the catalytically inactive mutant proE375A-gelatinase A were prepared as described previously (20, 31-33). Progelatinase B and pro(Delta 426-688)gelatinase B were prepared as described in Ref. 26. Stromelysin-1 and matrilysin were prepared as recombinant pro forms as described previously (34, 35). N-GL.C-SL was prepared as described previously (25). The preparation of gelatinase A mutants N-G.C-SGG and N-G.C-SGS was as described previously (36). Gelatinase A and gelatinase A C-terminal domain mutants were activated at 100 µg/ml with 2 mM 4-aminophenylmercuric acetate for 1 h at 25 °C. Stromelysin-1 was activated with trypsin using the standard method (37). Gelatinase B and (Delta 426-688)gelatinase B were activated at 2 µM with 0.1 µM active stromelysin-1 at 37 °C for 2 h. Matrilysin was activated at 22 µg/ml with 1 mM 4-aminophenylmercuric acetate at 37 °C for 1 h.

Kinetic Studies-- Active enzymes were active site titrated against a standard preparation of TIMP-1 (20). TIMP-2 and TIMP-3 were active site titrated with stromelysin-1 that had been titrated against the standard TIMP-1. Assays were performed at 25 °C for gelatinase A and gelatinase B or at 37 °C for stromelysin-1 and matrilysin in a buffer containing 50 mM Tris-HCl, pH 7.5, 100 mM NaCl, 10 mM CaCl2, and 0.05% Brij 35 (fluorometry buffer). Hydrolysis of 1 µM substrate Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 for the gelatinases and matrilysin or Mca-Pro-Leu-Ala-Nva-Dpa-Ala-Arg-NH2 for stromelysin-1 was followed using a Perkin Elmer LS 50B fluorescence spectrometer (20, 25, 38). Inhibition of the matrix metalloproteinases by TIMPs was analyzed under pseudo-first-order conditions using suitable ratios of enzymes:inhibitors as described previously (20, 25). Association rate constants (kon) were estimated from the progress curves using published equations (20, 25) and the Enzfitter (Biosoft) or Grafit (Erithacus Software) program. The effect of ionic strength was analyzed by increasing the concentration of NaCl in the standard buffer from 0.1 M to 0.25 M and 0.5 M. For competition assays, various concentrations of (Delta 1-414)gelatinase A or proE375A-gelatinase A were added to the cuvette with the gelatinase A before the addition of TIMP-2 or TIMP-3. Because the Ki values for the TIMP:gelatinase A interaction are unknown, the Ki and the Kd for the TIMP:competitor interaction are expressed as relative values using an arbitrary value of 1 for the Ki. The relationship between the two dissociation constants is given in Equation 1:
K<SUB>d</SUB>=<FR><NU>(F<SUB><UP>f</UP></SUB> · EI)</NU><DE>(FI · E<SUB><UP>f</UP></SUB>)</DE></FR> · K<SUB>i</SUB> (Eq. 1)
in which EI and Ef are the TIMP:gelatinase A complex and free gelatinase A, respectively, whereas FI and Ff are the TIMP:competitor complex and free competitor, respectively. Equation 1 can be rewritten as:
K<SUB>d</SUB>=<FR><NU>(F<SUB><UP>t</UP></SUB>−FI)(E<SUB><UP>t</UP></SUB>−E<SUB><UP>f</UP></SUB>)</NU><DE>(I<SUB><UP>t</UP></SUB>−[E<SUB><UP>t</UP></SUB>−E<SUB><UP>f</UP></SUB>]−I<SUB><UP>f</UP></SUB>) · E<SUB><UP>f</UP></SUB></DE></FR> · K<SUB>i</SUB> (Eq. 2)
in which Ft, Et, and It are total reagent concentrations. In our assays, Ft>> FI, and If is negligible, so Equation 2 can be simplified to Equation 3, from which the relative Kd can be readily calculated.
K<SUB>d</SUB>=<FR><NU>F<SUB><UP>t</UP></SUB> · (E<SUB><UP>t</UP></SUB>−E<SUB><UP>f</UP></SUB>)</NU><DE>(I<SUB><UP>t</UP></SUB>−E<SUB><UP>t</UP></SUB>+E<SUB><UP>f</UP></SUB>) · E<SUB><UP>f</UP></SUB></DE></FR> · K<SUB>i</SUB> (Eq. 3)
The effect of various polyanions on the rate of association was carried out using a constant amount of enzyme and inhibitor (concentrations similar to those used to calculate the kon values listed in Table I) with increasing concentrations of each test polyanion in the fluorometry buffer.

Binding of TIMP-3 to Progelatinases-- TIMP-3 was incubated in the presence or absence of progelatinases in TCABN for 1-2 h at 25 °C. Complexes with progelatinases were isolated on gelatin-Sepharose that had been blocked with 0.2 mg/ml bovine serum albumin in TCABN. The column was washed with TCABN, and bound material was eluted with TCABN containing 15% dimethyl sulfoxide. Eluates were analyzed by rabbit collagenase diffuse collagen fibril assays (39) and reverse zymography (40).

Binding of TIMPs to Heparin-Agarose-- Approximately 1 µg of each TIMP was applied to heparin-agarose (blocked with 0.2 mg/ml bovine serum albumin) in TCABN buffer. Columns were washed with TCABN, and proteins were eluted stepwise with the same buffer containing 0.5 M NaCl and then 2 M NaCl. Bound and unbound fractions were analyzed for TIMP content by SDS-polyacrylamide gel electrophoresis and silver staining and by rabbit collagenase diffuse collagen fibril assay (39).

Deglycosylation of TIMPs-- 5 µg of TIMP-3 or TIMP-1 were incubated for 4 h at 37 °C in the presence or absence of 1250 units of PNGase F (New England Biolabs). TIMPs were diluted in fluorometry buffer and used in assays as above.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

We analyzed the inhibition of active gelatinase A, gelatinase B, stromelysin-1, and matrilysin by TIMP-3 using continuous fluorometric assays with the appropriate fluorescent peptide substrate (see "Experimental Procedures"). As discussed previously for TIMP-1 and TIMP-2 (20, 25), we were unable to obtain accurate values of Ki (<200 pM). Our measurements were therefore limited to the association rate constants (kon) at low reagent concentrations, over a range where the observed rate was linear with TIMP concentration. In Table I, the data are compared with kon values for TIMP-2 that were re-assayed at the same time and kon values for TIMP-1 derived from our previous work (25, 26). All three TIMPs bound relatively slowly to stromelysin-1 and matrilysin. In general, we found that TIMP-3 was more like TIMP-2 than TIMP-1, showing rapid binding to gelatinase A and slower association with gelatinase B. The contribution of the C-terminal domains of gelatinase A and gelatinase B to TIMP-3 binding was assessed by measuring the association rate of the isolated catalytic domains, (Delta 418-631)gelatinase A and (Delta 426-688)gelatinase B. Whereas TIMP-2 binding was only affected by the loss of the gelatinase A C-terminal domain, TIMP-3 association was slower in the absence of the C-terminal domains of both gelatinase A and gelatinase B (1400-fold and 12.5-fold, respectively).

                              
View this table:
[in this window]
[in a new window]
 
Table I
Comparison of the rate constants for the interaction of TIMPs with matrix metalloproteinases
Association rate constants (kon) were estimated from the inhibition progress curves using equations described previously (20, 25). The data for TIMP-1 were taken from our previous work [25, 26].

The effect of ionic strength on the rate of association of gelatinase A and TIMP-3 was analyzed at increasing NaCl concentrations. Similar to TIMP-2 (20), there was a marked decrease in kon from 16.0 × 106 M-1·s-1 in 0.1 M NaCl to 9.6 × 106 M-1·s-1 (0.25 M NaCl) and 7.3 × 106 M-1·s-1 (0.5 M NaCl), suggesting that ionic interactions are involved in the association of gelatinase A and TIMP-3.

The contribution of the C-terminal domain of gelatinase A to TIMP-3 binding was assessed by measuring the effect of adding increasing amounts of (Delta 1-414)gelatinase A (the isolated C-terminal domain) or proE375A-gelatinase A (an inactive form of progelatinase A) to the inhibition assay and observing the effect on the association rate for active full-length gelatinase A. The effect on inhibition by TIMP-2 was also measured for comparison. The increase in the final steady-state velocity and the decreased rate of inhibition observed with increasing concentrations of (Delta 1-414)gelatinase A and proE375A-gelatinase A were deduced to be due to an effective decrease in TIMP-3 concentration by binding to the C-terminal domain, as was seen for TIMP-2 (20). The data were analyzed as described under "Experimental Procedures" to obtain an estimate for Kd, the dissociation constant, relative to the Ki for the appropriate TIMP:gelatinase A interaction (Table II). The interaction of TIMP-3 with (1-414)gelatinase A was significant but was around 16-fold weaker than the interaction of TIMP-2. The interaction between TIMP-3 and proE375A-gelatinase A was about five times weaker than that for TIMP-2. In both cases, the interaction of the TIMPs with proE375A-gelatinase A was stronger than that with the isolated C-terminal domain, which suggests that additional sites of interaction exist in the proenzyme-TIMP complex.

                              
View this table:
[in this window]
[in a new window]
 
Table II
Estimation of the dissociation constant for binding of (Delta 1-414)gelatinase A or proE375A-gelatinase A to TIMP-3 and TIMP-2
Inhibition assays were carried out at 25 °C with increasing amounts of either (Delta 1-414)gelatinase A or proE375A-gelatinase A. The dissociation constant (Kd) was estimated as described under "Experimental Procedures" and is given as a relative value compared to that of the appropriate TIMP:gelatinase A interaction. n is the number of assays carried out.

To further characterize the region of gelatinase A responsible for the C-terminal domain interaction, we used two C-terminal domain mutants: regions of the C-terminal domain of gelatinase A were exchanged for the corresponding regions of the C-terminal domain of stromelysin-1, which does not interact significantly with the TIMPs (25). As was the case for TIMP-2 (36), replacement of residues 418-474 in N-G.C-SGG did not affect the rate of association with TIMP-3 (kon = 17.0 × 106 M-1·s-1, compared with 16.5 × 106 M-1·s-1 for gelatinase A). However, the additional substitution of residues 568-631 in N-G.C-SGS reduced the rate of association of TIMP-3 with gelatinase A by a factor of 100 to 0.1 × 106 M-1·s-1, suggesting that residues 568-631 of gelatinase A are crucial for the interaction with TIMP-3.

Because the kinetic data suggested that TIMP-3 has significant interactions with the hemopexin domains of gelatinase A and gelatinase B, we assessed the ability of TIMP-3 to bind to various pro form constructs of gelatinases A and B, in which normal catalytic domain interactions are precluded due to the presence of the propeptide domain (Table III). A small amount of TIMP-3 alone bound to the gelatin-Sepharose matrix. Enhanced retention of TIMP-3 was observed after preincubation with progelatinase A or progelatinase B, suggesting that TIMP-3 shows significant binding to both proenzymes. TIMP-3 was recovered in the unbound fraction after incubation with pro(Delta 418-631)gelatinase A or pro(Delta 426-688)gelatinase B. TIMP-3 bound to gelatin-Sepharose after preincubation with proN-G.C-SGG but did not bind if proN-G.C-SGS or proN-GL.C-SL were used. TIMP-2 was retained on the gelatin-Sepharose after incubation with progelatinase A but not after incubation with progelatinase B. 

                              
View this table:
[in this window]
[in a new window]
 
Table III
Analysis of complex formation between TIMP-3 and progelatinases A and B using gelatin-Sepharose
Each proenzyme was incubated for 1-2 h at 25 °C in an approximate 1:1 molar ratio with 1 µg of TIMP-2 or TIMP-3. Complexes of TIMP bound to proenzyme were isolated on gelatin-Sepharose that had been blocked with bovine serum albumin. TIMP activity in the bound and unbound fractions was measured in a rabbit collagenase diffuse fibril assay (39), and values are expressed as the percentage of total activity recovered for each incubation.

The Effect of Heparin on the Rate of Association of TIMPs with Gelatinase A-- Increasing concentrations of heparin in the fluorometry buffer reproducibly resulted in a bell-shaped distribution for the association rate of TIMP-3 with gelatinase A (Fig. 1a). As the heparin concentration was increased to 100 µg/ml, the association rate increased 3.7-fold compared with the kon measured in the absence of heparin. Further increases in the amount of heparin resulted in a decrease in the rate of association to levels approaching that observed in the absence of heparin. The addition of heparin to TIMP-2 and gelatinase A had a negligible effect on the association rate. The association rate of TIMP-1 and gelatinase A was increased by 4.6-fold with 800 µg/ml heparin, but the distribution was not bell-shaped, as it was for TIMP-3. Although TIMP-1 appears to be more dramatically affected than TIMP-3 due to the manner in which the data is presented, the kon for TIMP-3 increased to 108 M-1·s-1 and exceeds the maximum rate accurately measurable using this system, whereas values for TIMP-1 plateaued at around 2 × 107 M-1·s-1. Preincubation of either TIMP-3 or gelatinase A with heparin or the addition of heparin to the buffer did not affect the association rate obtained. Increasing amounts of heparin did not affect the association rate of (Delta 418-631)gelatinase A and TIMP-3 (data not shown). SDS-polyacrylamide gel electrophoresis and silver staining (data not shown) and a rabbit collagenase diffuse collagen fibril assay revealed that TIMP-1 and TIMP-2 did not bind at all to heparin-agarose in 0.15 M NaCl, whereas TIMP-3 did bind, and 95% was eluted by 0.5 M NaCl, and 5% was eluted by 2 M NaCl.


View larger version (11K):
[in this window]
[in a new window]
 
Fig. 1.   Comparison of the effects of increasing concentrations of polyanions on the rate of association of TIMPs with gelatinase A. Gelatinase A was inhibited using the following: (a) TIMP-1 (black-square), TIMP-2 (open circle ), or TIMP-3 () with increasing amounts of heparin; (b) TIMP-3 with increasing amounts of dextran sulfate () or heparan sulfate (open circle ); and (c) TIMP-3 with increasing amounts of heparin (black-square) or de-N-sulfated heparin (). Association rate constants were estimated, and the data are presented as the change in kon relative to the kon in the absence of heparin, because the enzyme concentration was constant but only approximate.

The TIMPs are differentially glycosylated by our NS0 cell expression system: TIMP-2 is nonglycosylated, TIMP-1 is glycosylated, and TIMP-3 is produced in glycosylated and nonglycosylated forms. The potential role of glycosylation in binding to the polyanions was investigated by comparing the effect of heparin on the inhibition of gelatinase A by TIMP-1 and TIMP-3 in their glycosylated and deglycosylated forms. After treatment of TIMP-1 and TIMP-3 with PNGase F, which cleaves off the carbohydrate at its link with asparagine, there was a decrease in the apparent molecular weight of both TIMP-3 and TIMP-1, giving a distinct band on a silver-stained 12% polyacrylamide gel, but no decrease in apparent molecular weight where the inhibitors were incubated under the same conditions without PNGase F (data not shown). This suggests that the carbohydrate had been removed. Using the collagenase fibril assay, we found that 98% of both glycosylated and deglycosylated TIMP-3 bound heparin-agarose in 0.15 M NaCl and both were eluted by 0.5 M NaCl, whereas neither form of TIMP-1 bound significantly. In the fluorimetric assay, PNGase F had no activity against Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2, and neither gelatinase A activity nor the rate of inhibition of gelatinase A by TIMP-1 was affected by the addition of PNGase F (data not shown). Deglycosylation of TIMP-1 and TIMP-3 had no effect on the rate of inhibition of gelatinase A in either the presence or absence of heparin (data not shown). Hence, it appears that the carbohydrate component of TIMP-1 and TIMP-3 is not responsible for the effect seen with heparin.

To confirm that the effect of heparin is mediated by ionic interactions, the ionic strength of the fluorimetry buffer was increased, and the association rate of TIMP-3 and gelatinase A was measured. Increasing the NaCl concentration from 0.1 M to 0.25 M or 0.5 M in the presence of 10 µg/ml heparin abolished the effect of heparin on the association rate: in 0.1 M NaCl, heparin increased the kon 1.4-fold, whereas in 0.25 M NaCl and 0.5 M NaCl, the kon was identical in the presence and absence of heparin. TIMP-3 was also eluted from heparin-agarose by 0.5 M NaCl. Raising the ionic strength had an identical effect on deglycosylated TIMP-3 in the presence or absence heparin (data not shown). This indicates that the effect of heparin is mediated by ionic interactions, probably between its negatively charged sulfate groups and the positively charged residues in TIMP-3 and gelatinase A.

The Effect of Other Polyanions on the Inhibition of Gelatinase A by TIMP-3-- The effect of various polyanions on the rate of association of TIMP-3 with gelatinase A was tested using the standard fluorometric assay. Like heparin, dextran sulfate resulted in a bell-shaped distribution for the association rate over the concentration range studied, with an increase in kon of 4.4-fold at 50 µg/ml dextran sulfate (Fig. 1b). Heparan sulfate resulted in a slight increase in the association rate over the relatively small concentration range studied (Fig. 1b). Hyaluronic acid and dermatan sulfate had no effect, although the former did result in an increase in the steady-state rate, probably due to increasing viscosity (data not shown). There was no effect on the rate of association of TIMP-3 and gelatinase A when de-N-sulfated heparin was used (Fig. 1c).

The Effect of Heparin on the Rate of Association of TIMP-3 and Other MMPs-- The association rate of TIMP-3 and stromelysin-1 was not affected by heparin over the concentration range of 0-800 µg/ml (data not shown), probably because stromelysin does not bind to heparin (34). The rate of interaction of TIMP-3 with matrilysin was increased 2-fold by heparin, but the rate did not decrease with high heparin concentrations, as it did for gelatinase A, and de-N-sulfated heparin also increased the association rate slightly (Fig. 2a). There was also a slight increase in the rate of association with heparan sulfate, hyaluronic acid (as well as an increase in the steady-state rate as for gelatinase A), and dermatan sulfate (data not shown). Dextran sulfate increased the association rate 15-fold, and the distribution was bell-shaped, as it was for gelatinase A (Fig. 2b). However, the pattern of these results differed from those of TIMP-3 and gelatinase A, suggesting a different mode of action for the effect on TIMP-3 and matrilysin.


View larger version (12K):
[in this window]
[in a new window]
 
Fig. 2.   The effect of polyanions on the interaction of TIMP-3 and matrilysin. 314 pM matrilysin was inhibited using 5.22 nM TIMP-3 at 37 °C in the presence of increasing concentrations of (a) heparin () or de-N-sulfated heparin (open circle ) and (b) dextran sulfate. Association rate constants (kon) were estimated from the inhibition progress curves as described under "Experimental Procedures."


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Our data show that TIMP-3 is able to associate with the MMPs stromelysin-1 and matrilysin with rates similar to TIMP-1 and TIMP-2: the association rate is relatively slow (105 M-1·s-1), presumably because stromelysin-1 has negligible C-terminal domain interactions with TIMPs (17, 25), and matrilysin comprises solely a catalytic domain. The interaction of TIMP-3 with active gelatinase A (107 M-1·s-1) and gelatinase B (105 M-1·s-1) is more similar to that of TIMP-2. The rate of association of TIMP-3 with these gelatinases is enhanced by the hemopexin domains of the enzymes. The apparent Kd data suggest that significant interactions occur between the C-terminal domain of gelatinase A and TIMP-3. The interaction between TIMP-3 and the C-terminal domain of gelatinase A is slightly weaker than that of TIMP-2, probably due to the absence of the highly negatively charged C-terminal tail in TIMP-3 that is present in TIMP-2 (these last 8 residues of TIMP-2 have been shown to be highly significant in the interaction with the C-terminal domain of gelatinase A (20)), but serves to increase the rate of association of TIMP-3 and gelatinase A 1000-fold. As for TIMP-2 (36), C-terminal domain interactions with residues 568-631 are particularly important for rapid association of TIMP-3 and gelatinase A. The decrease in the rate of inhibition of gelatinase A by TIMP-3 with increasing ionic strength suggests the involvement of charged residues in the interaction, as seen for TIMP-2 (20). We also reported previously that TIMP-3 inhibition of the catalytic domains of MT1 MMP and MT2 MMP was similar to that of TIMP-2 (41, 42). It is known that TIMP-2 and TIMP-4 bind to progelatinase A via C-terminal domain interactions (20, 43). Here we demonstrate that TIMP-3 is also able bind to progelatinase A. Complex formation between TIMP-3 and progelatinase A involves C-terminal domain interactions: the binding of progelatinase A to TIMP-3 was reduced by removal of the hemopexin domain or by replacement with the C-terminal domain of stromelysin-1. As with the active enzyme, residues 568-631 but not residues 418-474 of the hemopexin domain play an important role in the association of progelatinase A and TIMP-3. These residues constitute part of blade 3 and the whole of blade 4 in the four-bladed propeller structure determined by x-ray crystallography (44, 45) and border a surface patch of lysine residues (residues 566, 567, and 568) that may be important for the electrostatic interaction. This region was also important for the association of gelatinase A with TIMP-2 (36) and suggests that TIMP-2 and TIMP-3 share common features of the binding site for progelatinase A. Although TIMP-3 is able to bind progelatinase A and MT1 MMP (41) like TIMP-2, we have been unable to convincingly demonstrate its involvement in progelatinase A activation as we did for TIMP-2 (36). It is unclear whether this is due to technical difficulties caused by the adherent nature of TIMP-3 or an alternative pericellular activation pathway involving TIMP-3 bound to the matrix or whether the binding of TIMP-3 to progelatinase A is not strong enough to support the formation of a membrane receptor (36).

Removal of the C-terminal domain of gelatinase B significantly reduced the rate of inhibition of this enzyme by TIMP-3. Hence, as for TIMP-1 (26), the hemopexin domain of gelatinase B is important for association with TIMP-3, although it contributes little to the association with TIMP-2. Like TIMP-1 (26), TIMP-3 can also bind to progelatinase B, but not to pro(Delta 426-688)gelatinase B, indicating that these C-terminal domain interactions are sufficient and necessary to yield a stable proenzyme-inhibitor complex. The precise biological role of this property of the TIMPs is not yet known, although a role in progelatinase B activation is possible.

The assays of TIMP-3 inhibitory activity described above were carried out in solution. Although these studies are valuable from a comparative point of view, it must also be borne in mind that TIMP-3 is apparently largely extracellular matrix-bound in vivo, although the components to which it binds remain to be determined. Proteoglycans consist of core proteins with numerous attached glycosaminoglycan chains: the latter are negatively charged polysaccharides composed of repeating disaccharides (for reviews, see Refs. 46 and 47). TIMP-3 possesses 9 positively charged residues (8 lysines and 1 arginine) that are not present in TIMP-1 or TIMP-2 (see alignment, Fig. 3 in Ref. 3) and that are generally conserved in TIMP-3 from different species. It is likely that these charged residues may be involved in the interaction of TIMP-3 with cell surface or extracellular matrix glycosaminoglycans. We therefore tested the effect of some commercially available polyanions on the inhibition of various MMPs by TIMP-3.

The rate of inhibition of gelatinase A but not (Delta 418-631)gelatinase A by TIMP-3 was increased by heparin. Both gelatinase A and TIMP-3 bind to heparin, but there is no heparin binding site in (Delta 418-631)gelatinase A (48), suggesting that a heparin binding site is required in both interacting proteins. The bell-shaped distribution of the association rate over the heparin concentration range studied is reminiscent of similar curves for the effect of heparin on progelatinase A autoactivation (48) or for the inhibition of thrombin by antithrombin III (49). The curve suggests a biomolecular mode of binding to heparin that increases the local concentration of reactants, thereby increasing their rate of interaction, rather than a conformational effect.

The effects of the polyanions tested on the rate of inhibition of gelatinase A by TIMP-3 appear to correlate with negative charge density. The sulfated compounds, dextran sulfate, heparin, and heparan sulfate (4-5 O-linked, 2-3 O- and N-linked and 1 O- or N-linked sulfate per disaccharide, respectively (50)), enhanced the rate of interaction, whereas dermatan sulfate (1 O-linked sulfate per disaccharide), de-N-sulfated heparin, and hyaluronic acid (unsulfated) had no effect, suggesting that the interaction of enzyme and inhibitor with these polyanions is based on charge density as well as structure. A specific recognition domain in heparin has been described for basic fibroblast growth factor and antithrombin (51). The existence of such a domain for TIMP-3 would be compatible with a surface concentration mechanism like that of antithrombin and thrombin (51). TIMP-3 does not contain any of the reported linear heparin binding motifs, but a motif defined by the three-dimensional structure could exist (52). It is likely that TIMP-3 interacts with cell surface and extracellular matrix glycosaminoglycans via the large number of positively charged residues in TIMP-3, and that this is the basis for its location in the extracellular matrix both in vivo and in cell culture. Hence, colocalization of TIMP-3 with proenzymes in the pericellular environment may be a mechanism for increasing the rate of inhibition of MMPs and regulating extracellular matrix breakdown during morphogenetic processes.

Heparan sulfate proteoglycans such as perlecan (53) and syndecans (54) are also implicated in binding growth factors that promote angiogenesis. A recent study demonstrated that TIMP-3 can inhibit endothelial cell migration and angiogenesis in response to the angiogenic factors basic fibroblast growth factor and vascular endothelial growth factor (55). TIMP-2 had similar effects upon endothelial cell migration in vitro, but TIMP-1 was ineffective (55, 56). This implicates MT1 MMP in the angiogenic process, an enzyme that can degrade matrix components and initiate the autoactivation of gelatinase A (36, 40, 57). The study presented here suggests that the effects of TIMP-3 and TIMP-2 might be due to the specific ability of these inhibitors to bind to progelatinase A as well as to inhibit MT1 MMP. Colocalization of TIMP-3 in the pericellular environment via binding to the extracellular matrix, including heparan sulfate proteoglycans, would place this inhibitor in a key position to inhibit MMPs produced by endothelial cells, thus regulating degradation of the extracellular matrix and release of the angiogenic factors required for migration and angiogenesis.

    ACKNOWLEDGEMENTS

We thank Dr. Tom Crabbe for the kind gifts of (Delta 1-414)gelatinase A and (Delta 418-631)gelatinase A and Dr. C. G. Knight for synthesis of the quenched fluorescent substrates.

    FOOTNOTES

* This work was supported by the Wellcome Trust, the Arthritis and Rheumatism Campaign, United Kingdom, and The Arthritis Foundation, U.S.A.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

parallel An Arthritis and Rheumatism Campaign Senior Fellow.

** To whom correspondence should be addressed. Tel.: 44-1603-593811; Fax: 44-1603-592250; E-mail: g.murphy{at}uea.ac.uk.

2 J. O'Connell and G. Murphy, unpublished data.

    ABBREVIATIONS

The abbreviations used are: TIMP, tissue inhibitor of metalloproteinases; MMP, matrix metalloproteinase; (Delta 1-414)gelatinase A, C-terminal domain of gelatinase A; (Delta 418-631)gelatinase A, N-terminal domain of gelatinase A; proE375A-gelatinase A, catalytically inactive mutant of gelatinase A; (Delta 426-688)gelatinase B, N-terminal domain of gelatinase B; N-G.C-SGG, gelatinase A mutant with residues 418-474 replaced with residues 248-305 of stromelysin-1; N-G.C-SGS, as N-G.C-SGG but with the additional replacement of residues 568-631 of gelatinase A with residues 400-460 of stromelysin-1; N-GL.C-SL, gelatinase A residues 1-417 fused with residues 248-460 of stromelysin-1; TCABN, 50 mM Tris, pH 7.5, 150 mM NaCl, 10 mM CaCl2, 0.025% Brij 35, and 0.02% azide; MT, membrane type.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
  1. Docherty, A. J. P., Lyons, A., Smith, B. J., Wright, E. M., Stephens, P. E., Harris, T. J. R., Murphy, G., and Reynolds, J. J. (1985) Nature 318, 66-69[Medline] [Order article via Infotrieve]
  2. Boone, T. C., Johnson, M. J., DeClerck, Y. A., and Langley, K. E. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 2800-2804[Abstract]
  3. Apte, S. S., Mattei, M.-G., and Olsen, B. R. (1994) Genomics 19, 86-90[CrossRef][Medline] [Order article via Infotrieve]
  4. Silbiger, S. M., Jacobsen, V. L., Cupples, R. L., and Koski, R. A. (1994) Gene (Amst.) 141, 293-297[Medline] [Order article via Infotrieve]
  5. Uria, J. A., Ferrando, A. A., Velasco, G., Freije, J. M. P., and Lopez-Otin, C. (1994) Cancer Res. 54, 2091-2094[Abstract]
  6. Wilde, C. G., Hawkins, P. R., Coleman, R. T., Levine, W. B., Delegeane, A. M., Okamoto, P. M., Ito, L. Y., Scott, R. W., and Seilhamer, J. J. (1994) DNA Cell Biol. 13, 711-718[Medline] [Order article via Infotrieve]
  7. Greene, J., Wang, M., Lin, Y. E., Raymond, L. A., Rosen, C., and Shi, Y. E. (1996) J. Biol. Chem. 271, 30375-30380[Abstract/Free Full Text]
  8. Blenis, J., and Hawkes, S. P. (1983) Proc. Natl. Acad. Sci. U. S. A. 80, 770-774[Abstract]
  9. Staskus, P. W., Masiarz, F. R., Pallanck, L. J., and Hawkes, S. P. (1991) J. Biol. Chem. 266, 449-454[Abstract/Free Full Text]
  10. Kishnani, N. S., Staskus, P. W., Yang, T. T., Masiarz, F. R., and Hawkes, S. P. (1994) Matrix Biol. 14, 479-488
  11. Wick, M., Bürger, C., Brüsselbach, S., Lucibello, F. C., and Müller, R. (1994) J. Biol. Chem. 269, 18953-18960[Abstract/Free Full Text]
  12. Ward, R. V., Hembry, R. M., Reynolds, J. J., and Murphy, G. (1991) Biochem. J. 278, 179-187[Medline] [Order article via Infotrieve]
  13. Apte, S. S., Olsen, B. R., and Murphy, G. (1995) J. Biol. Chem. 270, 14313-14318[Abstract/Free Full Text]
  14. Cawston, T. E., Galloway, W. A., Mercer, E., Murphy, G., and Reynolds, J. J. (1981) Biochem. J. 195, 159-165[Medline] [Order article via Infotrieve]
  15. Welgus, H. G., Campbell, E. J., Bar-Shavit, Z., Senior, R. M., and Teitelbaum, S. L. (1985) J. Clin. Invest. 76, 219-224[Medline] [Order article via Infotrieve]
  16. Okada, Y., Nagase, H., and Harris, E. D., Jr. (1986) J. Biol. Chem. 261, 14245-14255[Abstract/Free Full Text]
  17. Murphy, G., and Willenbrock, F. (1995) Methods Enzymol. 248, 496-510[Medline] [Order article via Infotrieve]
  18. Williamson, R. A., Marston, F. A. O., Angal, S., Koklitis, P., Panico, M., Morris, H. R., Carne, A. F., Smith, B. J., Harris, T. J. R., and Freedman, R. B. (1990) Biochem. J. 268, 267-274[Medline] [Order article via Infotrieve]
  19. Murphy, G., Houbrechts, A., Cockett, M. I., Williamson, R. A., O'Shea, M., and Docherty, A. J. P. (1991) Biochemistry 30, 8097-8102[Medline] [Order article via Infotrieve]
  20. Willenbrock, F., Crabbe, T., Slocombe, P. M., Sutton, C. W., Docherty, A. J. P., Cockett, M. I., O'Shea, M., Brocklehurst, K., Phillips, I. R., and Murphy, G. (1993) Biochemistry 32, 4330-4337[Medline] [Order article via Infotrieve]
  21. DeClerck, Y. A., Yean, T. D., Lee, Y., Tomich, J. M., and Langley, K. (1993) Biochem. J. 289, 65-69[Medline] [Order article via Infotrieve]
  22. Gomis-Rüth, F. X., Maskos, K., Betz, M., Bergner, A., Huber, R., Suzuki, K., Yoshida, N., Nagase, H., Brew, K., Bourenkow, G. B., Bartunik, H., and Bode, W. (1997) Nature 389, 77-81[CrossRef][Medline] [Order article via Infotrieve]
  23. Leliévre, Y., Bouboutou, R., Boiziau, J., Faucher, D., Achard, D., and Cartwright, T. (1990) Matrix 10, 292-299[Medline] [Order article via Infotrieve]
  24. Murphy, G., and Willenbrock, F. (1995) Methods Enzymol. 248, 496-510[Medline] [Order article via Infotrieve]
  25. Nguyen, Q., Willenbrock, F., Cockett, M. I., O'Shea, M., Docherty, A. J. P., and Murphy, G. (1994) Biochemistry 33, 2089-2095[Medline] [Order article via Infotrieve]
  26. O'Connell, J. P., Willenbrock, F., Docherty, A. J. P., Eaton, D., and Murphy, G. (1994) J. Biol. Chem. 269, 14967-14973[Abstract/Free Full Text]
  27. Collier, I. E., Willhelm, S. M., Eisen, A. Z., Marmer, B. L., Grant, G. A., Seltzer, J. L., Kronberger, A., He, C., Bauer, E. A., and Goldberg, G. I. (1988) J. Biol. Chem. 263, 6579-6587[Abstract/Free Full Text]
  28. Howard, E. W., and Banda, M. J. (1991) J. Biol. Chem. 266, 17972-17977[Abstract/Free Full Text]
  29. Goldberg, G. I., Strongin, A., Collier, I. E., Genrich, L. T., and Marmer, B. L. (1992) J. Biol. Chem. 267, 4583-4591[Abstract/Free Full Text]
  30. Kleiner, D. E., Unsworth, E. J., Krutzsch, H. C., and Stetler-Stevenson, W. G. (1992) Biochemistry 31, 1665-1672[Medline] [Order article via Infotrieve]
  31. Ward, R. V., Atkinson, S. J., Reynolds, J. J., and Murphy, G. (1994) Biochem. J. 304, 263-269[Medline] [Order article via Infotrieve]
  32. Murphy, G., Willenbrock, F., Ward, R. V., Cockett, M. I., Eaton, D., and Docherty, A. J. P. (1992) Biochem. J. 283, 637-641[Medline] [Order article via Infotrieve]
  33. Crabbe, T., Zucker, S., Cockett, M. I., Willenbrock, F., Tickle, S., O'Connell, J. P., Scothern, J. M., Murphy, G., and Docherty, A. J. P. (1994) Biochemistry 33, 6684-6690[Medline] [Order article via Infotrieve]
  34. Koklitis, P. A., Murphy, G., Sutton, C., and Angal, S. (1991) Biochem. J. 276, 217-221[Medline] [Order article via Infotrieve]
  35. Crabbe, T., Willenbrock, F., Eaton, D., Hynds, P., Carne, A. F., Murphy, G., and Docherty, A. J. P. (1992) Biochemistry 31, 8500-8507[Medline] [Order article via Infotrieve]
  36. Butler, G. S., Butler, M. J., Atkinson, S. J., Will, H., Tamura, T., Schade van Westrum, S., Crabbe, T., Clements, J., d'Ortho, M. P., and Murphy, G. (1998) J. Biol. Chem. 273, 871-880[Abstract/Free Full Text]
  37. Koklitis, P. A., Murphy, G., Sutton, C., and Angal, S. (1991) Biochem. J. 276, 217-221[Medline] [Order article via Infotrieve]
  38. Knight, C. G., Willenbrock, F., and Murphy, G. (1992) FEBS Lett. 296, 263-266[CrossRef][Medline] [Order article via Infotrieve]
  39. Murphy, G., Cawston, T. E., Galloway, W. A., Barnes, M. J., Bunning, R. A. D., Mercer, E., Reynolds, J. J., and Burgeson, R. E. (1981) Biochem. J. 199, 807-811[Medline] [Order article via Infotrieve]
  40. Atkinson, S. J., Crabbe, T., Cowell, S., Ward, R. V., Butler, M. J., Sato, H., Seiki, M., Reynolds, J. J., and Murphy, G. (1995) J. Biol. Chem. 270, 30479-30485[Abstract/Free Full Text]
  41. Will, H., Atkinson, S. J., Butler, G. S., Smith, B., and Murphy, G. (1996) J. Biol. Chem. 271, 17119-17123[Abstract/Free Full Text]
  42. Butler, G. S., Will, H., Atkinson, S. J., and Murphy, G. (1997) Eur. J. Biochem. 244, 653-657[Abstract]
  43. Bigg, H. F., Shi, Y. E., Liu, Y. E., Steffensen, B., and Overall, C. M. (1997) J. Biol. Chem. 272, 15496-15500[Abstract/Free Full Text]
  44. Libson, A. M., Gittis, A. G., Collier, I. E., Marmer, B. L., Goldberg, G. I., and Lattman, E. E. (1995) Nat. Struct. Biol. 2, 938-942[Medline] [Order article via Infotrieve]
  45. Gohlke, U., Gomis-Rüth, F. X., Crabbe, T., Murphy, G., Docherty, A. J. P., and Bode, W. (1996) FEBS Lett. 378, 126-130[CrossRef][Medline] [Order article via Infotrieve]
  46. Höök, M., Kjellén, L., Johansson, S., and Robinson, J. (1984) Annu. Rev. Biochem. 53, 847-869[CrossRef][Medline] [Order article via Infotrieve]
  47. Gallagher, J. T., Lyon, M., and Steward, W. P. (1986) Biochem. J. 236, 313-325[Medline] [Order article via Infotrieve]
  48. Crabbe, T., Ioannou, C., and Docherty, A. J. P. (1993) Eur. J. Biochem. 218, 431-438[Abstract]
  49. Evans, D. L., Marshall, C. J., Christey, P. B., and Carrell, R. W. (1992) Biochemistry 31, 12629-12642[Medline] [Order article via Infotrieve]
  50. Alter, S. C., Metcalfe, D. D., Bradford, T. R., and Schwartz, L. B. (1987) Biochem. J. 248, 821-827[Medline] [Order article via Infotrieve]
  51. Gallagher, J. T. (1995) in Glycoimmunology (Alavi, A., and Axford, J. S., eds), pp. 125-134, Plenum Press, New York
  52. Margalit, H., Fischer, N., and Ben-Sasson, S. A. (1993) J. Biol. Chem. 268, 19228-19231[Abstract/Free Full Text]
  53. Iozzo, R. V., Cohen, I. R., Grassel, S., and Murdoch, A. D. (1994) Biochem. J. 302, 625-639[Medline] [Order article via Infotrieve]
  54. Salmivirta, M., and Jalkanen, M. (1995) Experientia (Basel) 51, 863-872
  55. Anand-Apte, B., Pepper, M. S., Voest, E., Montesano, R., Olsen, B., Murphy, G., Apte, S., and Zetter, B. (1997) Invest. Opthalmol. Visual Sci. 38, 817-823[Abstract]
  56. Murphy, A. N., Unsworth, E. J., and Stetler-Stevenson, W. G. (1993) J. Cell. Physiol. 157, 351-358[Medline] [Order article via Infotrieve]
  57. d'Ortho, M. P., Will, H., Atkinson, S., Butler, G., Messent, A., Gavrilovic, J., Smith, B., Timpl, R., Zardi, L., and Murphy, G. (1997) Eur. J. Biochem. 250, 751-757[Abstract]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.